South Korea is establishing a new health insurance reimbursement standard for Rimkato while simultaneously tightening eligibility criteria for Kymriah, according to a report from kpanews.co.kr.
The Health Insurance Review and Assessment Service plans to implement these revised guidelines on December 1, adding Rimkato monotherapy to the non-Hodgkin lymphoma reimbursement criteria.
Under the upcoming changes, both CAR-T cell therapies will restrict reimbursement to patients who have never received prior CAR-T treatment.
The newly proposed reimbursement for Rimkato targets adult patients with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma who experience relapse or refractory disease after two or more lines of systemic therapy. The treatment applies to third-line therapy and later, provided patients have no history of prior CAR-T cell therapy.
Refractory status requires confirmed disease progression regardless of chemotherapy cycles, or a failure to achieve a complete response after at least three cycles of chemotherapy when hematopoietic stem cell transplantation is not feasible.
For Kymriah, the reimbursement criteria for non-Hodgkin lymphoma remove existing administration notes and add specific refractory definitions. Adult patients with diffuse large B-cell lymphoma must experience relapse or refractory disease after two or more systemic treatments and have no prior CAR-T exposure.
Pediatric and young adult patients up to age 25 with B-cell acute lymphoblastic leukemia face an added requirement specifying they must not have received prior CAR-T cell therapy for post-transplant relapse, second relapse, or subsequent refractory disease, according to Kpanews.
| Therapy | Target Indication | Key Restriction |
|---|---|---|
| Rimkato | Adult DLBCL and PMBCL (3rd line+) | No prior CAR-T experience |
| Kymriah | Adult non-Hodgkin lymphoma | No prior CAR-T experience |
| Kymriah | Pediatric and young adult ALL | No prior CAR-T experience |
The agency is also removing several existing annotations from the Kymriah reimbursement guidelines. Provisions duplicating the Ministry of Food and Drug Safety approvals and high-cost drug management criteria are being streamlined.
The Health Insurance Review and Assessment Service was established in 2000 to handle claims review and quality assessment for the National Health Insurance, later taking on claims review for Medical Aid, Veterans Hospitals, and auto insurance. Its headquarters moved from Seoul to Wonju in 2015, and it now operates 10 branch offices nationwide.
These removals eliminate specific monitoring clauses tied to reimbursement implementation history for both non-Hodgkin lymphoma and acute lymphoblastic leukemia treatments.
Keep reading